GNMLF Stock Genomma Lab International SAB DE CV (GNMLF, $0.95) was a top loser this quarter, falling -18.8%
at Tickeron.com
Loading...
Genomma Lab International SAB DE CV (GNMLF, $0.95) was a top loser over the last three months, falling to $0.95 per share. A.I.dvisor analyzed 216 stocks in the Pharmaceuticals: Generic Industry for the 3-month period ending November 10, 2025, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.
GNMLF in -3.64% downward trend, declining for three consecutive days on November 04, 2025
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GNMLF declined for three days, in of 7 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GNMLF as a result. In of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
GNMLF moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GNMLF crossed bearishly below the 50-day moving average on October 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
GNMLF broke above its upper Bollinger Band on October 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GNMLF entered a downward trend on November 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNMLF's RSI Oscillator exited the oversold zone, of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for GNMLF just turned positive on October 29, 2025. Looking at past instances where GNMLF's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.540) is normal, around the industry mean (18.827). P/E Ratio (10.587) is within average values for comparable stocks, (71.764). Projected Growth (PEG Ratio) (0.463) is also within normal values, averaging (1.856). Dividend Yield (0.044) settles around the average of (0.031) among similar stocks. P/S Ratio (0.974) is also within normal values, averaging (39.291).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GNMLF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNMLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Advertisement
General Information
Industry PharmaceuticalsGeneric